Global Metabolic Disorders Therapeutics Market, By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy, Others), Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Metabolic Disorders Therapeutics Market Analysis and Size
The metabolic disorders therapeutics market is projected to witness major growth during the forecast period. Increasing cases of hypertension, cardiomyopathy, diabetes and hypercholesterolemia boost the metabolic syndrome market. Factors such as adaptation of unhealthy lifestyle, increased stress in daily life & malnutrition and family history with cardiac disease are also increasing the market growth. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the metabolic disorders therapeutics market in the forecast period 2022-2029. The expected CAGR of metabolic disorders therapeutics market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 62 billion in 2021, and it would grow upto USD 110.58 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Metabolic Disorders Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy, Others), Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Atkins Global (U.S.), Herbalife International of America Inc., (U.S.), Nutrisystem Inc., (U.S.), Abbott (U.S.), Kellogg Co. (U.S.), mega Laboratories, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Medtronic (Ireland.), Apollo Endosurgery Inc., (U.S.), GSK plc (U.K), Olympus Corporation (India), WW International Inc., (U.S.), Jenny Craig (U.S.), Gold’s Gym (U.S.), DSM (Netherlands), Brunswick (U.S.), Amer Sports (Finland), Johnson Health Tech (U.S.), Technogym SpA (Italy), Shaklee Corporation (U.S.), Nature's Sunshine Products, Inc., (U.S.) and Novo Nordisk A/S (Denmark)
|
|
Market Opportunities
|
|
Market Definition
Metabolic syndrome is the condition of grouped diseases that occur together and increases the risk of heart disease, stroke and type 2 diabetes. These conditions involve high blood sugar, abnormal cholesterol level, increased blood pressure, excess body fat around the waist, increased blood pressure. Having one of the diseases doesn’t mean patient suffering from metabolic syndrome but, having two to three diseases at the same time increases the risk of metabolic syndrome. Symptom involves increased thirst & urination, blurred vision and fatigue. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Global Metabolic Disorders Therapeutics Market Dynamics
Drivers
- Rising Awareness For Disease Treatment
Increasing awareness among patients and several healthcare professionals for the treatment of different types of metabolic syndromes and more and more usage of combination therapy are the major factors that are expected to boost the demand for global metabolic syndrome market during the forecast period of 2022-2029.
- Increased Clinical Studies and Government Initiatives
The global metabolic syndrome market is projected to be driven by the rising R&D investments in drug discovery and development and the increasing prevalence of diabetes. For instance, as per the reports of International Diabetes Federation, for the treatment of diabetes as a metabolic syndrome, about 415 million people are currently affected by diabetes worldwide and it is hoped to increase to 642 million diabetic people by the year 2040.
Opportunities
- Increasing Demand for Retail Pharmacies
Increase in the number of metabolic syndromes therapeutics being delivered through retail pharmacies and rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Rising Demand of Drug Therapy
The drug therapy is driving the market because of its extensive usage as a result if ease of administration and high-reliability rate. This therapy is anticipated to maintain its growth even due to its advanced ways of administering medicines without disturbing daily patient lives. Furthermore, the launch of smart drug delivery devices and smart dosage control methods are projected to boost the segment further.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could reduce the growth of the global metabolic disorders therapeutics market over a forecast period.
- High Cost
The huge expenditure of the treatment methods hamper the market growth.
This global metabolic disorders therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global metabolic disorders therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Metabolic Disorders Therapeutics Market
The Covid-19 pandemic let a negative impact on the global metabolic disorders therapeutics market because the utmost priority was given to Covid-19 patients for treatment. Numerous medical colleges and hospitals were reorganised and helped in the structure so that they can accommodate more patients diagnosed with Covid-19. Discovery and development of drugs for the types of metabolic syndromes also slowed down during the pandemic, but it wasn’t in a pause and now in the post pandemic era, it is growing again.
Global Metabolic Disorders Therapeutics Market Scope
The global metabolic disorders therapeutics market is segmented on the basis of therapy type, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy Type
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Gene Therapy
- Drug Therapy
- Others
Application
- Lysosomal Storage Diseases
- Diabetes
- Obesity
- Hypercholesterolemia
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Metabolic Disorders Therapeutics Market Regional Analysis/Insights
The global metabolic disorders therapeutics market is analysed and market size insights and trends are provided by therapy type, application, distribution channel and end-user as referenced above.
The major countries covered in the global metabolic disorders therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increased geriatric population, and presence of key manufacture of the product.
Asia-Pacific dominates the market due to increased prevalence of coronary heart diseases and related disorders, increased awareness programmes on the healthy lifestyle and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Metabolic Disorders Therapeutics Market Share Analysis
The global metabolic disorders therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global metabolic disorders therapeutics market.
Key players operating in the global metabolic disorders therapeutics market include:
- Atkins Global (U.S.)
- Herbalife International of America Inc., (U.S.)
- Nutrisystem Inc., (U.S.)
- Abbott (U.S.)
- Kellogg Co. (U.S.)
- mega Laboratories, Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Medtronic (Ireland)
- Apollo Endosurgery Inc., (U.S.)
- GSK plc (U.K)
- Olympus Corporation (India)
- WW International Inc., (U.S.)
- jenny Craig (U.S.)
- Gold’s Gym (U.S.)
- DSM (Netherlands)
- Brunswick (U.S.)
- Amer Sports (Finland)
- Johnson Health Tech (U.S.)
- Technogym SpA (Italy)
- Shaklee Corporation (U.S.)
- Nature's Sunshine Products, Inc., (U.S.)
- Novo Nordisk A/S (Denmark)
SKU-